UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE‐1 (phase 2) Japanese cohort

Cancer science, 2022-12, Vol.113 (12), p.4267-4276

2022

Volltextzugriff (PDF)

The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies

Cancer reports, 2022-11, Vol.5 (11), p.e1603-n/a

2022

Volltextzugriff (PDF)

Design considerations in clinical trials with cure rate survival data: A case study in oncology

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2018-03, Vol.17 (2), p.94-104

2018

Volltextzugriff (PDF)

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

The Lancet (British edition), 2021-07, Vol.398 (10297), p.314-324

2021

Volltextzugriff (PDF)

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

The New England journal of medicine, 2023-07, Vol.389 (4), p.335-347

2023

Volltextzugriff (PDF)

S202: CARTITUDE‐1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e6102468-n/a

2023

Volltextzugriff (PDF)

S100: FIRST PHASE 3 RESULTS FROM CARTITUDE‐4: CILTA‐CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE‐REFRACTORY MULTIPLE MYELOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e471416f-n/a

2023

Volltextzugriff (PDF)

Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

Current medical research and opinion, 2021-10, Vol.37 (10), p.1779-1788

2021

Volltextzugriff (PDF)

Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

Current medical research and opinion, 2023-01, Vol.39 (1), p.81-89

2023

Volltextzugriff (PDF)

Peripheral neuropathy in HIV: prevalence and risk factors

AIDS (London), 2011-04, Vol.25 (7), p.919-928

2011

Volltextzugriff (PDF)

Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study

Clinical lymphoma, myeloma and leukemia, 2023-12, Vol.23 (12), p.882-888

2023

Volltextzugriff (PDF)

MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT)

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S411

2022

Volltextzugriff (PDF)

Ultrasound B-Mode Visualization of Imperceptible Subwavelength Vibration in Magnetomotive Ultrasound Imaging

Vibration, 2024-09, Vol.7 (3), p.764-775

2024

Volltextzugriff (PDF)

Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study

The Lancet. Haematology, 2022-12, Vol.9 (12), p.e897-e905

2022

Volltextzugriff (PDF)

MM-181 CARTITUDE-1: Two-Year Post Last Patient in (LPI) Results From the Phase 1b/2 Study of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S410-S411

2022

Volltextzugriff (PDF)

Progressive sharing of multiple images with sensitivity-controlled decoding

EURASIP journal on advances in signal processing, 2015-02, Vol.2015 (1), p.1-19, Article 11

2015

Volltextzugriff (PDF)

Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals

Journal of neurovirology, 2011-02, Vol.17 (1), p.17-25

2011

Volltextzugriff (PDF)

Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087

Journal of clinical lipidology, 2010-07, Vol.4 (4), p.279-287

2010

Volltextzugriff (PDF)

B-mode subwavelength vibration imaging

2017 IEEE International Ultrasonics Symposium (IUS), 2017, p.1-1

2017

Volltextzugriff (PDF)

Comparative Analysis of Methods for Analyzing Clinical Results of Immuno-Oncology Therapy with Delayed Treatment Effects

Blood, 2023-11, Vol.142 (Supplement 1), p.7167-7167

2023

Volltextzugriff (PDF)

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

Blood, 2022-11, Vol.140 (Supplement 1), p.4652-4654

2022

Volltextzugriff (PDF)

B-mode subwavelength vibration imaging

2017 IEEE International Ultrasonics Symposium (IUS), 2017, p.1-4

2017

Volltextzugriff (PDF)

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(81)

Publikationsform

Sprache

Englisch
(87)
Chinesisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE‐1 (phase 2) Japanese cohort

The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Design considerations in clinical trials with cure rate survival data: A case study in oncology

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

S202: CARTITUDE‐1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

S100: FIRST PHASE 3 RESULTS FROM CARTITUDE‐4: CILTA‐CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE‐REFRACTORY MULTIPLE MYELOMA

Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

Peripheral neuropathy in HIV: prevalence and risk factors

Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study

MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT)

Ultrasound B-Mode Visualization of Imperceptible Subwavelength Vibration in Magnetomotive Ultrasound Imaging

Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study

MM-181 CARTITUDE-1: Two-Year Post Last Patient in (LPI) Results From the Phase 1b/2 Study of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Progressive sharing of multiple images with sensitivity-controlled decoding

Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals

Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087

B-mode subwavelength vibration imaging

Comparative Analysis of Methods for Analyzing Clinical Results of Immuno-Oncology Therapy with Delayed Treatment Effects

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

B-mode subwavelength vibration imaging

Clinical Experience with Cranial Nerve Impairment in the CARTITUDE-1, CARTITUDE-2 Cohorts A, B, and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel)

Suchergebnisse filtern